Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Juvista (avotermin) with scar revision surgery for improvement of disfiguring scars
2008-002124-28Phase 3Completed
- Sponsor
- Renovo
- Start
- Oct 2008
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of avotermin in scar and severe cutaneous adverse reactions (SCAR), sponsored by Renovo. Primary endpoint: Primary scar appearance improvement at 12 months. Started Oct 2008; status: completed.
02
Drugs
avotermin
03
Conditions
scarsevere cutaneous adverse reactions (SCAR)
Beyond the preview
Go deeper on 2008-002124-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-002124-28.